Positive News SentimentPositive NewsNASDAQ:TNYA Tenaya Therapeutics (TNYA) Stock Price, News & Analysis $0.59 -0.02 (-3.25%) Closing price 04:00 PM EasternExtended Trading$0.58 0.00 (-0.81%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Tenaya Therapeutics Stock (NASDAQ:TNYA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Tenaya Therapeutics alerts:Sign Up Key Stats Today's Range$0.57▼$0.6150-Day Range$0.61▼$0.8252-Week Range$0.53▼$2.35Volume6.05 million shsAverage Volume3.46 million shsMarket Capitalization$132.25 millionP/E RatioN/ADividend YieldN/APrice Target$4.00Consensus RatingModerate Buy Company Overview Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for cardiovascular diseases. The company uses gene therapy, gene editing and small-molecule approaches to address the underlying causes of inherited and acquired heart conditions rather than treating symptoms alone. Tenaya’s product candidates include TN-201, an adeno-associated virus gene replacement therapy being developed for patients with MYBPC3-associated hypertrophic cardiomyopathy, and TN-401, a gene therapy candidate designed to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy. The company also maintains discovery programs intended to identify additional therapies for serious cardiac diseases. Founded in 2016 and headquartered in South San Francisco, California, Tenaya conducts research and clinical development activities in the United States. The company was co-founded by cardiovascular researchers, including Deepak Srivastava, and is led by Chief Executive Officer Faraz Ali. Its therapies are being developed for patients with genetically driven heart diseases for which available treatment options remain limited.AI Generated. May Contain Errors. Read More Tenaya Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreTNYA MarketRank™: Tenaya Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 590th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingModerate Buy Consensus RatingTenaya Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 1 strong buy rating, 5 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialTenaya Therapeutics has a consensus price target of $4.00, representing about 578.2% upside from its current price of $0.59.Amount of Analyst CoverageTenaya Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Tenaya Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Tenaya Therapeutics are expected to grow in the coming year, from ($0.38) to ($0.37) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tenaya Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tenaya Therapeutics is -1.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTenaya Therapeutics has a P/B Ratio of 1.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Tenaya Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted9.90% of the float of Tenaya Therapeutics has been sold short.Short Interest Ratio / Days to CoverTenaya Therapeutics has a short interest ratio ("days to cover") of 12.77, which indicates bearish sentiment.Change versus previous monthShort interest in Tenaya Therapeutics has recently increased by 4.17%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTenaya Therapeutics does not currently pay a dividend.Dividend GrowthTenaya Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News SentimentN/A News SentimentTenaya Therapeutics has a news sentiment score of 1.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tenaya Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 9 people have searched for TNYA on MarketBeat in the last 30 days. This is a decrease of -10% compared to the previous 30 days.MarketBeat Follows8 people have added Tenaya Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Tenaya Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $21,056.00 in company stock.Percentage Held by Insiders2.53% of the stock of Tenaya Therapeutics is held by insiders.Percentage Held by Institutions90.54% of the stock of Tenaya Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tenaya Therapeutics' insider trading history. Receive TNYA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tenaya Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. TNYA Stock News HeadlinesTenaya Therapeutics Announces RMAT Designation To TN-401September 14, 2026 | rttnews.comTenaya's TN-401 Receives FDA RMAT Status For PKP2-Associated Cardiomyopathy; Stock UpSeptember 14, 2026 | rttnews.comManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 in one quarter. Institutions own about 83% of shares, including BlackRock's 32 million shares worth $716 million and Vanguard's 48 million shares worth nearly $1.1 billion. A new multi-year deal with Palantir adds an AI-driven edge to this energy producer's operations.September 28 at 1:00 AM | Monument Traders Alliance (Ad)Tenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular ...September 14, 2026 | finance.yahoo.comTenaya Therapeutics Granted U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathySeptember 14, 2026 | globenewswire.comTenaya op H.C. Wainwright-conferentie: gentherapiedataSeptember 11, 2026 | nl.investing.comTenaya Therapeutics Corporate Event Calendar | NASDAQ:TNYASeptember 11, 2026 | benzinga.comTenaya Therapeutics to Participate in Upcoming September Investor ConferencesSeptember 3, 2026 | globenewswire.comSee More Headlines TNYA Stock Analysis - Frequently Asked Questions How have TNYA shares performed this year? Tenaya Therapeutics' stock was trading at $0.7115 at the start of the year. Since then, TNYA shares have decreased by 17.1% and is now trading at $0.5898. How were Tenaya Therapeutics' earnings last quarter? Tenaya Therapeutics, Inc. (NASDAQ:TNYA) issued its earnings results on Wednesday, August, 5th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.07) by $0.13. The business earned $1.11 million during the quarter, compared to analysts' expectations of $10 million. When did Tenaya Therapeutics IPO? Tenaya Therapeutics (TNYA) raised $180 million in an IPO on Thursday, July 29th 2021. The company issued 12,000,000 shares at a price of $14.00-$16.00 per share. Who are Tenaya Therapeutics' major shareholders? Top institutional shareholders of Tenaya Therapeutics include BlackRock Inc. (1.85%), Empery Asset Management LP (1.72%), GSA Capital Partners LLP (1.23%) and ADAR1 Capital Management LLC (0.69%). Insiders that own company stock include Faraz Ali, Timothy Hoey, Whittemore Tingley, Tomohiro Higa, Chihiro Saito and Group Gp Lp Column III. View institutional ownership trends. How do I buy shares of Tenaya Therapeutics? Shares of TNYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tenaya Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tenaya Therapeutics investors own include Voyager Therapeutics (VYGR), The RMR Group (RMR), iShares Micro-Cap ETF (IWC), Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH) and AUO (AUOTY). Company Calendar Last Earnings8/05/2026Today9/28/2026Next Earnings (Estimated)11/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 TNYA's financial health is in the Yellow zone, according to TradeSmith. TNYA has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:TNYA CIK1858848 Webwww.tenayatherapeutics.com Phone650-825-6990FaxN/AEmployees70Year Founded2016Price Target and Rating Average Price Target for Tenaya Therapeutics$4.00 High Price Target$8.00 Low Price Target$2.00 Potential Upside/Downside+578.2%Consensus RatingModerate Buy Rating Score (0-4)2.86 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$90.60 million Net MarginsN/A Pretax Margin-7,723.97% Return on Equity-83.75% Return on Assets-66.53% Debt Debt-to-Equity RatioN/A Current Ratio4.52 Quick Ratio4.52 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.57 per share Price / Book1.03Miscellaneous Outstanding Shares224,230,000Free Float218,557,000Market Cap$132.25 million OptionableOptionable Beta2.77 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:TNYA) was last updated on 9/28/2026 by MarketBeat.com Staff. From Our PartnersElon Musk’s Hushed FCC Filing. Dec 8th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the 50 range to 136 in eight months. This pa...Digest Publishing | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tenaya Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tenaya Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
